Search

Your search keyword '"Sternlicht, Hillel"' showing total 32 results
Start Over Author "Sternlicht, Hillel"
32 results on '"Sternlicht, Hillel"'

5. Contributors

Author

Agarwal, Rajiv, primary, Alfaadhel, Talal, additional, Andersen, Martin J., additional, Asplin, John Robert, additional, Avasare, Rupali S., additional, Bakris, George L., additional, Bansal, Amar D., additional, Baxi, Pravir V., additional, Berkoben, Michael, additional, Bieber, Scott D., additional, Buchkremer, Florian, additional, Burgner, Anna Marie, additional, Byrd, James Brian, additional, Cattran, Daniel, additional, Choudhury, Devasmita, additional, Granado, Rolando Claure-Del, additional, Denker, Bradley M., additional, Derebail, Vimal K., additional, Desnick, Robert J., additional, Lullo, Luca di, additional, Duronville, John V., additional, Eknoyan, Garabed, additional, Kateb, Mina El, additional, Elliott, William J., additional, Ennis, Jennifer L., additional, Fervenza, Fernando C., additional, Figlin, Robert A., additional, Galvin, Zita, additional, Garimella, Pranav S., additional, Gipson, Debbie S., additional, Gipson, Patrick E., additional, Goldfarb, David S., additional, Greenberg, Arthur, additional, Haller, Hermann, additional, Hiremath, Swapnil, additional, Horwitz, Edward J., additional, Hou, Susan, additional, Inker, Lesley A., additional, Irazabal, Maria V., additional, Irish, Ashley Bruce, additional, Jhaveri, Kenar D., additional, Jefferson, Jonathan Ashley, additional, Kalantar-Zadeh, Kamyar, additional, Kamil, Elaine S., additional, Kenny, Jon-Emile S., additional, Khoury, Charbel C., additional, Kohli, Jatinder, additional, Kovalik, Eugene C., additional, Kovesdy, Csaba P., additional, Kupin, Warren, additional, Lehrich, Ruediger W., additional, Lerma, Edgar V., additional, Levi, Moshe, additional, Lockridge, Joseph L., additional, Lopez, Jennifer, additional, Macedo, Etienne, additional, Mehrotra, Rajnish, additional, Mehta, Ravindra L., additional, Nachman, Patrick H., additional, Nadai, Carol, additional, Negrea, Lavinia Aura, additional, Nicolle, Lindsay E., additional, Norris, Keith C., additional, Novakovic, Alexander, additional, Olyaei, Ali J., additional, Pal, Sumanta Kumar, additional, Palevsky, Paul M., additional, Patel, Ami M., additional, Patney, Vikram, additional, Perazella, Mark A., additional, Pham, Phuong-Chi T., additional, Pham, Phuong-Thu T., additional, Pryor, Joseph B., additional, S. Ram, C. Venkata, additional, Rahman, MD, Mahboob, additional, Reisinger, Nathaniel, additional, Rocco, Michael V., additional, Ronco, Claudio, additional, Rosenberg, Mark E., additional, Rosner, Mitchell H., additional, Rudnick, Michael R., additional, Sabath, Ernesto, additional, Sarnak, Mark J., additional, Schell, Jane O., additional, Seay, N. Winn, additional, Sedor, John R., additional, Sethi, Akash Nair, additional, Shah, Anuja, additional, Shah, Lori, additional, Sherer, Benjamin A., additional, Singh, Harpreet, additional, Sinniah, Rajalingam, additional, Sloand, James A., additional, Sparks, Matthew A., additional, Sprague, Stuart M., additional, Steigerwalt, Susan Patricia, additional, Sternlicht, Hillel, additional, Stoller, Marshall L., additional, Thomas, Beje, additional, Toka, Hakan R., additional, Topf, Joel M., additional, Torres, Vicente E., additional, Trachtman, Howard, additional, Traynor, Carol, additional, Tucker, Bryan M., additional, Vogt, Beth A., additional, Wanchoo, Rimda, additional, Weir, Matthew R., additional, Whaley-Connell, Adam, additional, Whittier, William L., additional, Wish, Jay B., additional, Wong, Florence, additional, Wymer, David C., additional, Wymer, David T.G., additional, and Zand, Ladan, additional

Published
2019
Full Text
View/download PDF

7. Contributors

Author

Ali, Ailia W., primary, Alicic, Radica Z., additional, Amar, Laurence, additional, Anwaruddin, Saif, additional, Appel, Lawrence J., additional, August, Phyllis, additional, Azizi, Michel, additional, Bakris, George L., additional, Banegas, José R., additional, Bard, Robert L., additional, Barrett, Orit, additional, Benetos, Athanase, additional, Bernstein, Kenneth E., additional, Bhatt, Deepak L., additional, Biaggioni, Italo, additional, Blumenthal, Roger S., additional, Bobrie, Guillaume, additional, Brook, Robert D., additional, Byrd, J. Brian, additional, Carter, Barry L., additional, Cohen, Debbie L., additional, Cushman, William C., additional, De Leeuw, Peter Wilhelmus, additional, Ehret, Georg B., additional, Elliott, William J., additional, Ernst, Michael E., additional, Farooq, Muhammad U., additional, Faucon, Anne-Laure, additional, Fishbein, Lauren, additional, Flynn, Joseph T., additional, Fujita, Toshiro, additional, George, Mary G., additional, Gorelick, Philip B., additional, Gosmanova, Elvira O., additional, Grim, Carlene M., additional, Grim, Clarence E., additional, Gupta, Rajeev, additional, Hall, John E., additional, Hall, Michael E., additional, Hanevold, Coral D., additional, Harrison, David G., additional, Huang, Qi-Fang, additional, Hughes, Alun, additional, Joseph, Philip, additional, Kario, Kazuomi, additional, Karmali, Kunal N., additional, Kollias, Anastasios, additional, Laffin, Luke J., additional, Landsberg, Lewis, additional, Lloyd-Jones, Donald M., additional, Madjalian, Anne-Marie, additional, Malha, Line, additional, Mancia, Giuseppe, additional, McEvoy, John W., additional, Mensah, George A., additional, Milner, Ross, additional, Min, Jiangyong, additional, Ochoa, Juan Eugenio, additional, Ota, Takeyoshi, additional, Ott, Christian, additional, Parati, Gianfranco, additional, Pepine, Carl J., additional, Perkovic, Vlado, additional, Podymow, Tiina, additional, Rahimi, Kazem, additional, Ruilope, Luis Miguel, additional, Ruiz-Hurtado, Gema, additional, Schmieder, Roland E., additional, Shibata, Shigeru, additional, Smith, Steven M., additional, Sorrentino, Matthew J., additional, Stergiou, George S., additional, Sternlicht, Hillel, additional, Strollo, Patrick J., additional, Taler, Sandra J., additional, Tanaka, Akiko, additional, Textor, Stephen C., additional, Townsend, Raymond R., additional, Tuttle, Katherine R., additional, Wang, Ji-Guang, additional, Whelton, Seamus P., additional, White, William B., additional, Williams, Bryan, additional, Wolak, Talya, additional, Yamout, Hala, additional, Yancy, Clyde W., additional, Young, William F., additional, and Yusuf, Salim, additional

Published
2018
Full Text
View/download PDF

15. List of Contributors

Author

Adamczak, Marcin, primary, Ikizler, T. Alp, additional, Bailey, James L., additional, Baliga, Radhakrishna, additional, Bellomo, Rinaldo, additional, Bikhchandani, J., additional, Blackburn, George L., additional, Bushinsky, David A., additional, Campese, Vito M., additional, Cano, Noel J., additional, Carrero, Juan Jesús, additional, Chadban, Steve, additional, Chadha, Vimal, additional, Chan, Maria, additional, Chang, Alex, additional, Chazot, Charles, additional, Chmielewski, Michal, additional, Christov, Marta, additional, Chua, Horng-Ruey, additional, Chwastiak, Lydia, additional, Don, Burl R., additional, Druml, Wilfred, additional, Dukkipati, Ramanath, additional, Feldt-Rasmussen, Bo, additional, Finkelstein, Frederic, additional, Forse, R.A., additional, Fouque, Denis, additional, Franch, Harold A., additional, Garimella, Pranav S., additional, Grieff, Marvin, additional, Gutiérrez, Orlando M., additional, Haddad, Nabil, additional, Hebert, Lee A., additional, Heimbürger, Olof, additional, Hirschberg, Raimund, additional, Houston, Jessica, additional, Isakova, Tamara, additional, Jiwakanon, Sirin, additional, Kaysen, George A., additional, Kovesdy, Csaba P., additional, Kramer, Holly, additional, Kurokawa, Kiyoshi, additional, Landau, Daniel, additional, Li, Yinan, additional, Lindholm, Bengt, additional, Magerowski, Greta, additional, Martin, Kevin J., additional, Martin, Cathi J., additional, Martino, Steve, additional, Mehrotra, Rajnish, additional, Melamed, Michal L., additional, Mitch, William E., additional, Miyata, Toshio, additional, Molfino, Alessio, additional, Niwa, Toshimitsu, additional, Pupim, Lara B., additional, Rabkin, Ralph, additional, Raj, Dominic, additional, Rajapurkar, Mohan, additional, Raju, Samia, additional, Ritz, Eberhard, additional, Sarnak, Mark J., additional, Shah, Sudhir V., additional, Shim, Rosemarie, additional, Stanton, Robert, additional, Steiber, Alison l., additional, Stenvinkel, Peter, additional, Sternlicht, Hillel, additional, Storer, Thomas W., additional, Swaminathan, Sundararaman, additional, Thadhani, Ravi, additional, Vaziri, Nosratola D., additional, Velasquez, Manuel, additional, Voinescu, Alexandra, additional, Warady, Bradley A., additional, Weiner, Daniel E., additional, Wiecek, Andrzej, additional, Williams, Mark E., additional, Wing, Maria, additional, Wolf, Myles, additional, Workeneh, B., additional, and Zhang, Min, additional

Published
2013
Full Text
View/download PDF

17. Contributors

Author

Abramovitz, Blaise W., Agarwal, Rajiv, Ahmad, Sarah, Alexander, Matthew R., AlQassas, Ibrahim A., Arroyo, Juan P., Asuzu, Christopher, Ayesh, Ali, Bakris, George, Bali, Atul, Beckman, Joshua A., Bock, Fabian, Bugeja, Ann, Burgner, Anna, Carey, Robert M., Cohen, Jordana B., Concepcion, Beatrice P., Dillingham, Christine, Drager, Luciano F., Dresser, George K., Eknoyan, Garabed, Ellison, David, Erdbrugger, Uta, Farrell, Maureen C., Flood, Ryan P., Flynn, Joseph T., Georgianos, Panagiotis I., Gilligan, Sarah, McAuliffe, Christin Giordano, Hiremath, Swapnil, Holder, Tara A., Hu, Jiun-Ruey, Husain, Irma, Imran, Nashat, Judd, Eric, Kharadjian, Talar B., Kim, Esther S., Kovach, Cassandra, Kumar, Arun, Lerma, Edgar V., Lewis, Julia B., Libianto, Renata, Lloyd, Matthew, Luther, James M., Malhotra, Rakesh, Mehta, Hina N., Montford, John R., Mosley, Jonathan D., Munir, Bilal, Padwal, Raj, Patel, Trisha, Peixoto, Aldo J., Pradhan, Nishigandha, Pratt, J. Howard, Puar, Akshan, Rabkin, Simon W., Rahman, Mahboob, Raj, Satish R., Ramkumar, Nirupama, Rianto, Fitra, Ringrose, Jennifer, Ruzicka, Marcel, Schiavon, Carlos A., Shamy, Michel, Shawar, Saed, Shibao, Cyndya A., Sparks, Matthew A., Sternlicht, Hillel, Sussman, Craig, Terker, Andrew, Tezuka, Yuta, Tran, Karen C., Turcu, Adina F., Vaidya, Anand, and Yang, Jun

Published
2023
Full Text
View/download PDF

21. Hypercalcemia of malignancy and new treatment options

Author

Glezerman, Ilya G. and Sternlicht,Hillel

Subjects
Therapeutics and Clinical Risk Management
Abstract

Hillel Sternlicht,1 Ilya G Glezerman1,2 1Division of Nephrology and Hypertension, Weill Cornell Medical College, 2Renal Service, Memorial Sloan Kettering Cancer Center, NewYork, NY, USA Abstract: Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most frequently encountered manifestation of end organ damage. Symptomatology is closely linked to both the absolute elevation of serum calcium levels and the rapidity of calcium rise. The majority of cases are humoral in etiology and related to parathyroid hormone-related protein (PTHrP). Approximately 20% of cases are the result of direct bone metastasis with extra-renal 1,25-dihydroxyvitamin D (calcitriol) and ectopic parathyroid hormone production likely accounting for less than 1% of cases. The diagnosis of hypercalcemia of malignancy is confirmed either by an elevated PTHrP or by an evidence of bone metastasis in the appropriate clinical setting. Treatment is predicated on the patient’s symptoms and absolute serum calcium level. Interventions are aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration. Novel therapies for refractory disease include denosumab, a monoclonal antibody against the receptor activator of nuclear factor κB ligand, and the calcimimetic cinacalcet. Finally, anti-PTHrP antibodies have been successfully deployed in animal models of disease. Despite the efficacy of the above therapies, hypercalcemia of malignancy portends an ominous prognosis, indicating advanced and often refractory cancer with survival on the order of months. Keywords: hypercalcemia of malignancy parathyroid hormone, parathyroid hormone-related protein, calcitonin, bisphosphonates, denosumab, cinacalcet

Published
2015

22. Two cases of spontaneous remission of non-parasitic chyluria

Author

Mendu, Damodara Rao, primary, Sternlicht, Hillel, additional, Ramanathan, Lakshmi V., additional, Pessin, Melissa S., additional, Fleisher, Martin, additional, Dalbagni, Guido, additional, Jaimes, Edgar A., additional, Kaltsas, Anna, additional, and Glezerman, Ilya G., additional

Published
2017
Full Text
View/download PDF

27. Hypercalcemia of malignancy and new treatment options

Author

Sternlicht,Hillel, Glezerman,Ilya G, Sternlicht,Hillel, and Glezerman,Ilya G

Abstract

Hillel Sternlicht,1 Ilya G Glezerman1,2 1Division of Nephrology and Hypertension, Weill Cornell Medical College, 2Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most frequently encountered manifestation of end organ damage. Symptomatology is closely linked to both the absolute elevation of serum calcium levels and the rapidity of calcium rise. The majority of cases are humoral in etiology and related to parathyroid hormone-related protein (PTHrP). Approximately 20% of cases are the result of direct bone metastasis with extra-renal 1,25-dihydroxyvitamin D (calcitriol) and ectopic parathyroid hormone production likely accounting for less than 1% of cases. The diagnosis of hypercalcemia of malignancy is confirmed either by an elevated PTHrP or by an evidence of bone metastasis in the appropriate clinical setting. Treatment is predicated on the patient’s symptoms and absolute serum calcium level. Interventions are aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration. Novel therapies for refractory disease include denosumab, a monoclonal antibody against the receptor activator of nuclear factor κB ligand, and the calcimimetic cinacalcet. Finally, anti-PT

Published
2015

29. Hypercalcemia of malignancy and new treatment options.

Author

Sternlicht, Hillel and Glezerman, Ilya G.

Subjects
*HYPERCALCEMIA, *CANCER treatment, *CANCER risk factors, *CANCER patient medical care, *HEALTH of cancer patients, *THERAPEUTICS
Abstract

Hypercalcemia of malignancy affects up to one in five cancer patients during the course of their disease. It is associated with both liquid malignancies, commonly multiple myeloma, leukemia, and non-Hodgkins lymphoma and solid cancers, particularly breast and renal carcinomas as well as squamous cell carcinomas of any organ. The clinical manifestations of hypercalcemia are generally constitutional in nature and not specific to the inciting malignancy. Such physical manifestations can range from malaise to lethargy and confusion. Constipation and anorexia are common. Acute kidney injury is likely the most frequently encountered manifestation of end organ damage. Symptomatology is closely linked to both the absolute elevation of serum calcium levels and the rapidity of calcium rise. The majority of cases are humoral in etiology and related to parathyroid hormone-related protein (PTHrP). Approximately 20% of cases are the result of direct bone metastasis with extra-renal 1,25-dihydroxyvitamin D (calcitriol) and ectopic parathyroid hormone production likely accounting for less than 1% of cases. The diagnosis of hypercalcemia of malignancy is confirmed either by an elevated PTHrP or by an evidence of bone metastasis in the appropriate clinical setting. Treatment is predicated on the patient's symptoms and absolute serum calcium level. Interventions are aimed at lowering the serum calcium concentration by inhibiting bone resorption and increasing urinary calcium excretion, the former accomplished via bisphosphonate therapy and the latter with aggressive hydration. Novel therapies for refractory disease include denosumab, a monoclonal antibody against the receptor activator of nuclear factor κB ligand, and the calcimimetic cinacalcet. Finally, anti-PTHrP antibodies have been successfully deployed in animal models of disease. Despite the efficacy of the above therapies, hypercalcemia of malignancy portends an ominous prognosis, indicating advanced and often refractory cancer with survival on the order of months. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

31. SGLT2 inhibitors: not just another glucose-lowering agent.

Author

Sternlicht, Hillel and Bakris, George L.

Subjects
*SODIUM-glucose cotransporters, *BLOOD pressure, *HYPERTENSION, *THERAPEUTICS, *TYPE 2 diabetes, *DAPAGLIFLOZIN
Abstract

The article reports on a study regarding the sodium-glucose cotransporter 2(SGLT2) inhibitors that suggests that the SGLT2 inhibitors enhances the lowering of blood pressure on combining with antihypertensive therapy in patients with type 2 diabetes mellitus (T2DM). Topics discussed include reduction in blood pressure on administration of dapagliflozin in patients with T2DM, and the effect of SGLT2 inhibitors on anti-hypertensive drug classes.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results